



**BIOARRAY**  
GENETICS

Empowering Cancer Treatment Decisions


Marcia Fournier  
Founder and CEO

400 Farmington Avenue  
Farmington, CT 06032  
[Bioarray.us](http://Bioarray.us)

# If You Were Diagnosed with Cancer What Would You Like to Know?


- What are my chances?
- How severe is the cancer?
- What type of cancer?
- How to treat my cancer?

# Technology Agnostic Platform Designed to Rapidly Develop Proprietary Tests





# Development Test Portfolio Offers Large Market Opportunity

Number of Annual Eligible Patients




# BA-ER is a genomic test that measures Estrogen Receptor RNA expression



Accuracy >94%.  
Sensitivity 0.889  
Specificity 0.909  
Intra-assay precision R2 ≥0.90

# BA100 Will Stratify Patients with Predicted Residual Disease in Weeks instead of Months



Integrating BA100 with BRCA, PD-L1 testing creates \$277M/yr. market opportunity in the U.S.

RD: Residual Disease; pCR: pathological complete response;  
PPV: Positive predictive value; NPV: Negative predictive value  
Care pathway translated from SABC workshop: Triple-Negative Breast Cancer: Developing a More Positive Approach

# Intellectual Property Fully Owned by Bioarray

- ✓ International patents filed and issued for novel biomarkers libraries
  - Four family of international patents filed covering methods and tissue biomarkers
  - U.S. Patent Issued No. 9,771,618
  - U.S. Allowance; Application No. 13/983,767
  - EU Intent To Grant; Patent Application No. 12741540.4
- ✓ Provisional patents filed covering blood biomarkers
- ✓ Trade secrets on machine learning algorithms

# Bioarray Partnering Goals

- The company is currently seeking for an acquirer to take its assets to commercialization and scale.
  - Biomarker libraries relevant for at least 8 cancer types
  - Machine learning algorithms technology platform agnostic
  - BA-ER CLIA approved test
  - BA100Dx Triple Negative Breast Cancer Stratification Test clinical validation





# BIOARRAY GENETICS

Empowering Cancer Treatment Decisions

Marcia Fournier, CEO  
MVF@bioarray.us